ESC: MRI Shows Balloon Pumps don’t Reduce Infarct Size

AuntMinnie | Using MRI, researchers have found that intra-aortic balloon pump counterpulsation prior to percutaneous coronary intervention in patients with ST segment elevation myocardial infarction does not reduce infarct size, according to a study presented on Tuesday at the European Society of Cardiology (ESC) congress in Paris.

Results from the Counterpulsation Reduces Infarct Size Acute Myocardial Infarction (CRISP AMI) trial found good results for intra-aortic balloon counterpulsation (IABC), according to principal investigator Dr. Manesh Patel from the Duke Clinical Research Institute of Duke University in Durham, NC.

IABC is a procedure in which a balloon is inserted in the aorta and is timed to inflate at the start of diastole and to deflate before the start of systole. The procedure increases diastolic pressure, which in turn increases coronary perfusion and delivers oxygen to the myocardium, facilitating the ejection of blood from the left ventricle.

Previous research has shown that left ventricular unloading before reperfusion can reduce the extent of the infarction. Infarct size has been known to predict left ventricular function after acute myocardial infarction.

Of the 337 patients enrolled in the multicenter prospective trial, 161 subjects randomly received IABC prior to primary percutaneous coronary intervention (PCI). The other 176 patients received standard care (primary PCI without IABC support).

Results showed that mean infarct size was not significantly different between the IABC and standard care groups (42% versus 37%, representing the percentage of left ventricle affected). At 30-day follow-up, major bleeding or transfusion had occurred in five (3%) IABC patients and three (2%) standard care patients.

Major vascular complications occurred in seven IABC (4%) and two standard care (1%) patients. At six months, death had occurred in three (2%) of the IABC and nine (5.2%) of the standard care group.

While the study did not meet its primary end point and was not powered to draw significant conclusions on clinical events, the “most striking observation is the excellent overall outcome for the highest risk patients within the context of this trial,” Patel said. “The IABC group had less than 5% mortality, and it’s difficult to improve that.”

In the U.S., acute mortality risk in acute myocardial infarction is between 6% and 15%, with one-year mortality is estimated at 38% for women and 25% for men.


No Comments

Sorry, the comment form is closed at this time.